Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Sonidegib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 24 Mar 2025 Planned End Date changed from 1 Jul 2025 to 15 Nov 2026.
- 24 Mar 2025 Planned primary completion date changed from 1 Jul 2025 to 15 Jan 2026.
- 19 Mar 2025 Status changed from recruiting to active, no longer recruiting.